YARW (Yarrow Bioscience) Shares Outstanding (EOP): 0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
8 GF Score
Price $32.99
View Full Analysis

What is Yarrow Bioscience Shares Outstanding (EOP)?

Yarrow Bioscience YARW +8.34% 8 Shares Outstanding (EOP) is 0.00 Mil as of Dec. 2025. GuruFocus rates YARW with a GF Score™ of 8/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Yarrow Bioscience's shares outstanding for the quarter that ended in Dec. 2025 was 0.00 Mil.

Yarrow Bioscience's quarterly shares outstanding stayed the same from . 20 (0.00 Mil) to Dec. 2025 (0.00 Mil).

Yarrow Bioscience's annual shares outstanding stayed the same from . 20 (0.00 Mil) to Dec. 2025 (0.00 Mil).


Yarrow Bioscience  (NAS:YARW) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Yarrow Bioscience Shares Outstanding (EOP) Related Terms


Yarrow Bioscience Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience Shares Outstanding (EOP) Chart

Yarrow Bioscience Annual Data
Trend Dec25
Shares Outstanding (EOP)
0.00

Yarrow Bioscience Semi-Annual Data
Dec25
Shares Outstanding (EOP) 0.00

YARW vs : Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Yarrow Bioscience's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yarrow Bioscience Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Yarrow Bioscience's Shares Outstanding (EOP) falls into.


YARW
8GF Score
Yarrow Bioscience Inc YARW
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 0.00 Mil mean?
Yarrow Bioscience (YARW) has a Shares Outstanding (EOP) of 0.00 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Yarrow Bioscience and its competitors.
Is Yarrow Bioscience's Shares Outstanding (EOP) too high?
Yarrow Bioscience's current Shares Outstanding (EOP) is 0.00 Mil. Overall, Yarrow Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Shares Outstanding (EOP) compare to ?
Yarrow Bioscience's Shares Outstanding (EOP) of 0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Yarrow Bioscience and its competitors. Yarrow Bioscience's current Shares Outstanding (EOP) is 0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Shares Outstanding (EOP) of 0.00 Mil. The current Shares Outstanding (EOP) is 0.00 Mil. Yarrow Bioscience's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Shares Outstanding (EOP) is 0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Comparable Companies
Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
8GF Score

Get the complete analysis for YARW

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.99
Price